Register a trial

Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements. New passwords must include at least one lowercase letter, one uppercase letter, one number and one special character (e.g. !#$%&@).
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06961565




Registration number
NCT06961565
Ethics application status
Date submitted
11/04/2025
Date registered
8/05/2025

Titles & IDs
Public title
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Scientific title
A Phase 1/1b Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PAS-004, a MAPK/ERK Kinase 1/2 (MEK 1/2) Inhibitor, in Adult Participants With Neurofibromatosis Type 1 (NF1) With Symptomatic and Inoperable, Incompletely Resected, or Recurrent Plexiform Neurofibromas
Secondary ID [1] 0 0
PAS-004-103
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
NF1 Mutation 0 0
Neurofibroma Plexiform 0 0
Neurofibroma, Plexiform 0 0
Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs) 0 0
Neurofibromatosis Type 1 (NF1) 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Skin 0 0 0 0
Dermatological conditions
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PAS-004 Tablets

Experimental: Part A - Sequential dose escalation: 4 mg, 8 mg, 12 mg, and 18 mg

Experimental: Part B - Two parallel cohorts dosing at 2 levels selected based on Part A safety results


Treatment: Drugs: PAS-004 Tablets
A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 1m and 4mg strength tablets, intended for oral administration once daily.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part A: To evaluate the safety and tolerability of PAS-004 when administered for one 28-day treatment cycle
Timepoint [1] 0 0
Part A from enrollment (Day 1) through Day 28 (completion of Cycle 1)
Primary outcome [2] 0 0
Part B: To evaluate the safety and tolerability of PAS-004 when administered for six 28-day treatment cycle
Timepoint [2] 0 0
Part B from enrollment (Day 1) through Day 168 (completion of Cycle 6) [each cycle is 28 days]
Secondary outcome [1] 0 0
Peak Plasma Concentration (Cmax)
Timepoint [1] 0 0
Day 28 (predose, and 1 , 3 , 6 , and 24 hours post-dose) [end of Cycle 1]
Secondary outcome [2] 0 0
Plasma predose or trough concentration (Ctau/Ctrough)
Timepoint [2] 0 0
Day 28 (predose, and 1 , 3 , 6 , and 24 hours post-dose) [end of Cycle 1]
Secondary outcome [3] 0 0
Time of maximum plasma concentration (Tmax)
Timepoint [3] 0 0
Day 28 (predose, and 1 , 3 , 6 , and 24 hours post-dose) [end of Cycle 1]
Secondary outcome [4] 0 0
Area under the concentration versus time curve for the dosing interval, assuming steady state has been reached and duplicating the predose concentration for the 24 hour postdose concentration (AUC0-tau)
Timepoint [4] 0 0
Day 28 (predose, and 1 , 3 , 6 , and 24 hours post-dose) [end of Cycle 1]
Secondary outcome [5] 0 0
Evaluation of the percentage of extracellular signal-regulated kinase phosphorylation (pERK) inhibition from baseline
Timepoint [5] 0 0
Day 1 through Day 28 (Cycle 1), and at each subsequent 28-day cycle through Cycle 6 (D168) [each cycle is 28 days]
Secondary outcome [6] 0 0
Evaluation of the clinical benefit rate (CBR) over time on MRI with volumetric analysis of plexiform neurofibroma(s) using Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) criteria
Timepoint [6] 0 0
Screening (Baseline), Day 112 (End of Cycle 4), and Day 168 (End of Cycle 6) [each cycle is 28 days]
Secondary outcome [7] 0 0
Evaluation of the best objective response rate (ORR) over time on MRI with volumetric analysis of plexiform neurofibroma(s) using REiNS criteria
Timepoint [7] 0 0
Screening (Baseline), Day 112 (End of Cycle 4), and Day 168 (End of Cycle 6) [each cycle is 28 days]
Secondary outcome [8] 0 0
Evaluation of time to maximal response on MRI with volumetric analysis of plexiform neurofibroma(s) using the REiNS criteria
Timepoint [8] 0 0
Screening (Baseline), Day 112 (End of Cycle 4), and Day 168 (End of Cycle 6) [each cycle is 28 days]
Secondary outcome [9] 0 0
Evaluation of the appearance of cutaneous neurofibromas over time using photography
Timepoint [9] 0 0
Screening (Baseline), Day 112 (End of Cycle 4), and Day 168 (End of Cycle 6) [each cycle is 28 days]
Secondary outcome [10] 0 0
Evaluation of the size of cutaneous neurofibromas over time
Timepoint [10] 0 0
Screening (Baseline), Day 112 (End of Cycle 4), and Day 168 (End of Cycle 6) [each cycle is 28 days]
Secondary outcome [11] 0 0
Evaluation of changes from baseline on quality of life (QOL) using the Plexi-QOL survey
Timepoint [11] 0 0
Screening, and Days 28, 56, 84, 112, 140 and 168
Secondary outcome [12] 0 0
Evaluation of changes from baseline on any physical symptoms attributed to the target plexiform neurofibroma using the Patient-Reported Outcomes Measurement Information System (PROMIS©) Physical Function (PF) assessment
Timepoint [12] 0 0
Screening, and Days 28, 56, 84, 112, 140 and 168

Eligibility
Key inclusion criteria
1. Participant is capable of providing informed consent, which includes compliance with the requirements, prohibitions and restrictions listed in the informed consent form.
2. Participant has been informed both verbally and in writing about the objectives of the clinical study, the methods, the anticipated benefits, the potential risks, and the discomfort to which they may be exposed and has given written consent to participation in the study prior to study start and any study-related procedure.
3. Participant must be at least 18 years of age at the signing of the informed consent form (ICF).
4. Participant must be able to swallow oral medication.
5. Performance status: Participant must have a Karnofsky performance level of =70%. Note: Participants who are wheelchair bound because of paralysis secondary to a PN should be considered ambulatory when they are in the wheelchair. Similarly, participants with limited mobility secondary to the need for mechanical support (such as an airway PN requiring tracheostomy or CPAP) will also be considered ambulatory for the purposes of this study.
6. Participant has been diagnosed with NF1 based upon the following diagnostic criteria:

a. Clinical and imaging confirmation meeting at least two of the following NF1 diagnostic criteria in accordance with the clinical NIH consensus criteria: i. = Six cafe-au-lait macules > 1.5 cm in maximum diameter ii. Axillary and/or inguinal freckling iii. = Two neurofibromas of any type, or = 1 plexiform neurofibroma; iv. An optic pathway glioma (prior diagnosis without concurrent disease is acceptable) v. = Five Lisch nodules (iris hamartomas). Note: must be confirmed on slit lamp exam by an ophthalmologist if this is one of only two criteria met for diagnosis vi. A distinctive bony lesion such as dysplasia of the sphenoid bone or dysplasia or thinning of long bone cortex vii. Biologic parent with confirmed diagnosis of NF1 viii. Genetic testing demonstrating a pathogenic NF1 germline mutation per CLIA-certified laboratory (or equivalent) testing.

1. Note: NF1 germline pathologic mutation positive must either be confirmed by the central laboratory or have documentation of NF1 mutation issued by a CLIA-certified laboratory (or equivalent). 2. No concern by the Investigator that an NF1 mimic, including but not limited to Noonan Syndrome, Legius Syndrome, or schwannomatosis could potentially serve as a more likely diagnosis

7. Participants satisfying the NF1 diagnostic criteria outlined in Inclusion Criterion #6 must also meet one of the following criteria:

a. Participant has at least one symptomatic PN ("Target PN") measuring at least 3 cm on maximal cross-sectional (axial) diameter that is judged by the Investigator to be likely responsible for participant symptoms (such as pain, deformity, or neurologic disability), and unable to be completely resected without causing substantial damage/functional deficit, or unsuitable for surgery with high surgical risks.

b. Participant has an incompletely resected symptomatic PN with a postoperative residual of at least 15% of the primary lesion and measuring at least 3 cm on cross-sectional (axial) diameter.

c. Participant has a recurrent symptomatic PN measuring at least 3 cm in maximal cross-sectional (axial) dimension after prior resection.

8. Participants should have a minimum of seven measurable CN measuring 6-15 mm (if participants satisfy Inclusion Criterion #6 and have no CN or less than 7 CN they still might be considered for the study as judged by the Investigator and Sponsor).

1. Measurable is defined as: 1. non-pedunculated (no stalk) 2. surrounded by visually uninvolved skin and not in physical contact with another CN, 3. measuring between 6 and 15 mm in the longest diameter and exophytic on visual exam (not macular).
2. At least seven CN should be located on the trunk, neck, and/or limbs measuring between 6 and 15 mm in maximal diameter, and "measurable" as per the definition listed above.
3. Participants with CN meeting the above criteria will undergo optional resections of at least two CN that meet eligibility criteria. If participant is willing to accept additional CN resections, this is permitted for up to four additional lesions after completion of six PAS-004 treatment cycles or after early withdrawal as long as there are sufficient lesions to allow efficacy assessment.

9. Participant must be able and willing to undergo serial MRI scans as outlined in the study protocol.

Note: Anxiolytic medication or pain medication as deemed clinically appropriate by the Investigator is permissible for the purposes of managing anxiety, claustrophobia, and pain during MRI.

10. Participant must be able and willing to undergo serial 2-D and where available 3-D photography as well as caliper measurements as outlined in the study protocol.

11. Participant must have an international normalized ratio (INR) and activated partial thromboplastin time (APTT) = 1.5 x ULN.

12. Participant must have adequate organ and bone marrow function at screening as indicated by the following laboratory value ranges:

a. Absolute neutrophil count (ANC) = 1.5 × 109/L b. Hemoglobin = 90 g/dL c. Platelets = 100 × 109/L d. Serum total bilirubin = 1.5 × ULN for age (= 3.0 × ULN in participants with Gilbert's syndrome) e. Serum total bilirubin = 1.5 × ULN (Serum total bilirubin can be = 3.0 × ULN if participants have hemolysis or congenital hemolytic diseases) f. Aspartate aminotransferase (AST) = 2.0 × ULN g. Alanine aminotransferase (ALT) = 2.0 × ULN h. Albumin = 3 g/dL i. Creatinine clearance = 60 mL/min

13. Participant must either agree to maintain abstinence (no heterosexual intercourse), or to use one highly effective form of contraception during study treatment and for at least 90 days after the last dose of investigational product (IP). Sperm-producing participants must agree not to donate sperm while receiving IP and for at least 90 days after the last dose of IP.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Participant has participated in another interventional clinical study within 28 days of starting PAS-004.
2. Participant has received chemotherapy for any indication within 90 days of starting PAS-004.
3. Participant has ongoing side effects from prior chemotherapy that are worse than mild (except alopecia). ("Mild" is defined as Asymptomatic or mild symptoms, clinical or diagnostic observations only, or intervention not indicated.)
4. Participant has received treatment with any PN-directed drug or biologic therapy within 14 days of starting PAS-004.
5. Participant has received treatment with a strong CYP3A4 inhibitor or inducer, or moderate inducers for CYP2C8 and CYP2C9 within 14 days of starting PAS-004, or any drug considered a major substrate of the enzymes above with a narrow therapeutic index except for topical skin use, as judged by the Investigator and Sponsor.
6. Participant has received growth factors to increase the number or function of platelets or white blood cells within 7 days of starting PAS-004.
7. Participant has received radiotherapy, major surgery, or immunotherapy within 28 days of starting PAS-004.
8. Participant has malignant tumors associated with NF1 requiring chemotherapy, radiotherapy, or surgery, such as intermediate- to high-grade gliomas or malignant peripheral nerve sheath tumors.
9. Participant has a current malignancy (excluding cured non-melanomatous skin cancer, breast carcinoma in situ, or cervical cancer in situ) or has history of malignancy requiring active treatment within the past 5 years (excluding cured non-melanomatous skin cancer, breast carcinoma in situ, and cervical cancer in situ). Other tissue-limited low stage cancers can be assessed by the Sponsor for possible inclusion on a per-participant basis.
10. Participant has uncontrolled hypertension defined as blood pressures >150/90 mmHg on repeat examinations despite maximal medical management.

Note: Participants with controlled hypertension with anti-hypertension therapy are permitted, as judged by the Investigator and Sponsor.
11. Participant has active dysphagia, digestive system disease, malabsorption syndrome, or other conditions that might affect the absorption of PAS-004.
12. Participant has previous or current retinal vein occlusion (RVO), retinal pigment epithelial detachments (RPED), clinically active glaucoma, or other significant abnormality in screening ophthalmic examination.
13. Participant has interstitial pneumonia, NF1-related pulmonary disease, including existing clinically significant radiation pneumonitis.
14. Participant has impaired cardiac function or cardiac disease as indicated by:

1. Average QTc interval > 480 ms calculated using the Fridericia's QT interval correction formula.
2. Grade = 3 congestive heart failure per New York Heart Association (NYHA) guidelines.
3. Clinically significant arrhythmias, including but not limited to, complete left bundle branch conduction abnormalities and 2nd degree atrioventricular block.
4. Known concurrent clinically significant coronary artery disease, cardiomyopathy, or severe valvular disease.
5. Echocardiogram or multi-gated acquisition (MUGA) scan performed during the screening showing impaired left ventricular ejection fraction (LVEF) < 45%.
15. Participant has taken a QTc-prolonging medication within seven days of IP initiation or longer if the half-life of the QTc prolonging medication is such that the drug is not cleared from the body within 7 days (5 half-lives) of IP initiation.
16. Participant has an uncontrolled bacterial, fungal, or viral infections, including active hepatitis B (hepatitis B virus surface antigen positive and hepatitis B virus DNA > 1000 IU/ml or meeting the study site's diagnostic criteria for active hepatitis B infection), hepatitis C (hepatitis C virus RNA positive), or human immunodeficiency virus (HIV) infection with detectable viral load.
17. Any clinically significant active or known history of liver disease or known hepatobiliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
18. Participant has a known hypersensitivity to PAS-004, its excipients, or another MEK 1/2 inhibitor.
19. Participant is pregnant or lactating.
20. Participant has a clinically significant condition that, in the opinion of the investigator, would preclude study participation or compliance with safety requirements.
21. Participant is unable to attend in-person clinic visits per clinical site guidelines and restrictions.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
1/05/2025
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2027
Actual
Sample size
Target
56
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Royal North Shore Hospital - St Leonards
Recruitment postcode(s) [1] 0 0
2065 - St Leonards

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pasithea Therapeutics Corp.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Novotech (Australia) Pty Limited
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Tiago R Marques, MD
Address 0 0
Pasithea Therapeutics Corp.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06961565